Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis

International Journal of Antimicrobial Agents

Volumn 26, Issue 1, 2005, Pages 50-55

  Gous, Andries ^a   Lipman, Jeffrey ^b,e   Scribante, Juan ^c   Tshukutsoane, Shephelia ^c   Hon, Hubert ^c   Pinder, Mary ^c   Mathivha, Rudo ^c   Verhoef, Lia ^d   Stass, Heino ^d  

^a UNIVERSITY OF LIMPOPO   (South Africa)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Bayer (PTY and AG Germany)   (South Africa)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotics; Fluoroquinolone; Intensive Care Unit; Pharmacokinetics; Volume of distribution

Indexed keywords

CIPROFLOXACIN;

ABDOMINAL INFECTION; ADULT; ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE; MALE; PRIORITY JOURNAL; SEPSIS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BODY FLUID COMPARTMENTS; CIPROFLOXACIN; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; SEPSIS;

EID: 20744450631     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2005.04.005     Document Type: Article

References (21)

1. R. Davis, A. Markham, J.A. Balfour, and Ciprofloxacin An updated review of its pharmacology, therapeutic efficacy and tolerability Drugs 51 1996 1019 1074
2. J.S. Solomkin, H.H. Reinhart, and E.P. Dellinger Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group Ann Surg 223 1996 303 315
3. D.M. Campoli-Richards, J.P. Monk, A. Price, P. Benfield, P.A. Todd, and A. Ward Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 35 1988 373 447
4. P. Marik Aminoglycoside volume of distribution and illness severity in critically ill septic patients Anaesth Intensive Care 21 1993 172 173
5. P. Gosling, K. Sanghera, and G. Dickson Generalized vascular permeability and pulmonary function in patients following serious trauma J Trauma 36 1994 477 481
6. H.K. Nuytinck, X.J. Offermans, K. Kubat, and J.A. Goris Whole-body inflammation in trauma patients. An autopsy study Arch Surg 123 1988 1519 1524
7. Lipman J, Scribante J, Gous AGS, Hon H, Tshukutsoane S, and the Baragwanath Ciprofloxacin Study Group. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42:2235-9.
8. K.H. Bannefeld, H. Stass, and G. Blaschke Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high-performance liquid chromatography for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma J Chromatogr B Biomed Sci Appl 692 1997 453 459
9. A.G.S. Gous, M.D. Dance, J. Lipman, D.K. Luyt, L.R. Mathivha, and J. Scribante Changes in vancomycin pharmacokinetics in critically ill infants Anaesth Intensive Care 23 1995 678 682
10. E.E. Cornwell III, H. Belzberg, and T.V. Berne Aminoglycoside levels in critically ill surgical patients: the implication of physiologic criteria of sepsis South Med J 90 1997 33 36
11. C. Triginer, I. Izquirdo, and R. Fernandez Gentamicin volume of distribution in critically ill septic patients Intensive Care Med 16 1990 303 306
12. M. Hansen, L.L. Cristrup, J.O. Jarlov, J.P. Kampmann, and J. Bonde Gentamicin dosing in critically ill patients Acta Anaesthesiol Scand 45 2001 734 740
13. C. Brun-Buisson, and F. Lemaire Administration of antibiotics for pneumonia during respiratory failure: reaching the target Am J Respir Crit Care Med 164 2001 1554 1555
14. H. Georges, O. Leroy, and S. Alfandari Pulmonary disposition of vancomycin in critically ill patients Eur J Clin Microbiol Infect Dis 16 1997 385 388
15. J. Lipman, Gous AGS, and L.R. Mathivha Ciprofloxacin pharmacokinetic profiles in paediatric sepsis: how much ciprofloxacin is enough? Intensive Care Med 28 2002 493 500
16. A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrob Agents Chemother 37 1993 1073 1081
17. A. Shah, J. Lettieri, R. Blum, S. Millikin, D. Sica, and A.H. Heller Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects J Antimicrob Chemother 38 1996 103 116
18. Fink MP, Snydman DR, Niederman MS, et al., and the Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double blind trail comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994; 38:547-57.
19. Wilson APR, and R.N. Grüneberg Ciprofloxacin: 10 years of clinical experience 1997 Maxim Medical Oxford, UK p. 79-80
20. R. Rohwedder, T. Bergan, S.B. Thorsteinsson, and H. Scholl Transintestinal elimination of ciprofloxacin Chemotherapy 36 1990 77 84
21. E.M. Jones, C.M. McMullin, and A.J. Hedges The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease J Antimicrob Chemother 40 1997 121 124